NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts

Sanja Coso1, Ian Harrison, Craig B Harrison

  • 1Centre for Cancer Research, Monash Institute of Medical Research, Monash University, Victoria, Australia.

Abstract

Insights

Reactive oxygen species (ROS), primarily from NADPH oxidase enzymes, drive tumor angiogenesis by regulating cell signaling in tumor and immune cells. Targeting these ROS pathways offers new therapeutic strategies for cancer treatment.

Area of Science:

  • Cellular Biology
  • Cancer Research
  • Immunology

Background:

  • Reactive oxygen species (ROS) are endogenously produced by all mammalian cells.
  • Traditionally linked to macromolecular damage and cancer initiation.
  • Emerging roles in cell signaling, proliferation, differentiation, apoptosis, and immune cell function within the tumor microenvironment.

Purpose of the Study:

  • To highlight the role of NADPH oxidase enzymes as key sources of ROS.
  • To emphasize the involvement of ROS in tumor angiogenesis.
  • To explore therapeutic opportunities targeting ROS signaling in cancer.

Main Methods:

  • Review and synthesis of current literature on ROS and NADPH oxidases in cancer.
  • Focus on redox signaling pathways in tumor, endothelial, and immune cells.
  • Analysis of the role of ROS in angiogenesis and immune cell infiltration.

Main Results:

  • NADPH oxidase enzymes are identified as critical sources of ROS.
  • ROS generated by NADPH oxidases play a significant role in redox signaling.
  • These ROS signaling pathways are crucial for promoting tumor angiogenesis.

Conclusions:

  • Understanding ROS signaling and NADPH oxidases is key to developing novel cancer therapies.
  • Targeting ROS pathways may offer new strategies to prevent tumor angiogenesis.
  • This knowledge could also address revascularization after antiangiogenic treatments.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...